2H2026 Catalyst Cluster
The back half of 2026 is shaping up to be one of the denser catalyst windows we’ve seen in a while. Several names in…
Coverage
Blog
Latest research notes and coverage from the editorial archive.
Protara at a Crossroads
We increasingly see Protara Therapeutics (Nasdaq: TARA) at a crossroads. Earlier this week, the company hosted a KOL call in which it made a…
Equillium’s Turnaround: AHR, Abivax, and ADAR1
We are suckers for a good biotech turnaround story. You know the narrative: a once-ridiculed company that seemed headed toward certain failure or extinction,…
Rapid Fire Therapy: Quick Updates From Our Biotech Universe
Last month, we wrote what amounted to a full-length essay on Ovid Therapeutics (Nasdaq: OVID). We can be verbose and struggle with brevity. So…
Playbooks & Predictions: Xenon, Praxis, and Ovid
Last week, Xenon Pharmaceuticals (Nasdaq: XENE) announced compelling top-line results from the Phase 3 X-TOLE2 study with its lead asset, azetukalner, a Kv7 potassium…
Predicting Protara: Impending Data at Next Week’s ASCO-GU
Over the past two years, we have probably written about Protara Therapeutics (Nasdaq: TARA) more than any other company in our universe. The equity…
From Aduhelm’s Ashes: Two Affordable Alzheimer Names Targeting Toxic Oligomers
Investor interest in Alzheimer’s disease (AD) ebbs and flows more than in most indications. Most investors should agree that AD is an enormous, underserved…
Prediction Payoff: Ventyx Acquired, Plus Updates On Entera & Gain
In our last note, we made some fun predictions for a number of companies in our eclectic universe. Of all the predictions, the one…
Pipelines, Partnerships and Predictions For 2026
For a company with a modest ~$400 million market cap (we are including 10 million $5.25 warrants that should be exercised in 1H2026), Protara…
Big Ideas, Early Data, Imminent Results: Ovid & Gain
Big Brain Idea Before the end of the year, we expect Ovid Therapeutics (Nasdaq: OVID) to release Phase 1 safety data for its intravenous…